CAS NO: | 284464-77-3 |
包装 | 价格(元) |
1mg | 电议 |
5mg | 电议 |
10mg | 电议 |
Cas No. | 284464-77-3 |
化学名 | 2-(cyclohexylamino)-5-nitro-N-[(pentylamino)carbonyl]-benzenesulfonamide |
Canonical SMILES | CCCCCNC(=O)NS(=O)(=O)c1cc(ccc1NC1CCCCC1)[N](=O)O |
分子式 | C18H28N4O5S |
分子量 | 412.5 |
溶解度 | ≤10mg/ml in ethanol;20mg/ml in DMSO;20mg/ml in dimethyl formamide |
储存条件 | Store at -20℃ |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
产品描述 | IC50: 1.1 nM for TXA2 receptor antagonism BM 567 is acting as an inhibitor of thromboxane A2 (TXA2) synthase and an antagonist of the TP receptor. Thromboxane A2 (TXA2), a potent thrombogenic and vasoconstrictor eicosanoid, is produced in large quantities by activated platelets. TXA2 has been reported as a causal factor in the onset of stroke and myocardial infarction. In vitro: BM 567 was identified as a dual acting antithrombogenic agent, acting as an inhibitor of thromboxane A2 (TXA2) synthase and an antagonist of the TP receptor, the G protein-coupled receptor mediating TXA2 activity in platelets and vascular smooth muscle. BM 567 antagonized the vascular smooth muscle TP receptor with an IC50 value of 1.1 nM. BM 567 was also able to inhibit platelet TX synthase with an IC50 value of 12 nM. In addition, by comparing crystallographic and electronic properties of BM567 and terbogrel, two compounds with dual action (TXRA and TXSI), two essential anchoring identified: sulfonyl and nitro group for BM567 and carboxylate and pyridine nitrogen for terbogrel [1]. In vivo: Up to now, there is no animal in vivo data reported. Clinical trial: So far, no clinical study has been conducted. Reference: |